2022 Q3 Form 10-Q Financial Statement

#000155837022012034 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00 $66.81K
YoY Change
Gross Profit $0.00 $0.00 -$66.81K
YoY Change
Gross Profit Margin
Selling, General & Admin $2.772M $2.899M $3.821M
YoY Change -5.91% -7.15% -17.3%
% of Gross Profit
Research & Development $4.351M $6.395M $7.649M
YoY Change -30.63% 2.61% 5.24%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.124M $9.293M $11.47M
YoY Change -22.73% -0.78% -3.48%
Operating Profit -$7.124M -$9.293M -$11.54M
YoY Change
Interest Expense $733.8K $420.7K $615.8K
YoY Change 11.17% -30.19% -157.01%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.390M -$8.873M -$10.85M
YoY Change -25.34% 1.39% -16.28%
Income Tax -$66.15K -$45.77K $0.00
% Of Pretax Income
Net Earnings -$6.324M -$8.827M -$10.85M
YoY Change -26.12% 0.85% -16.28%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20 -$0.25
Diluted Earnings Per Share -$143.5K -$0.20 -$0.25
COMMON SHARES
Basic Shares Outstanding 44.07M 44.06M 44.03M
Diluted Shares Outstanding 44.06M 44.03M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $167.2M $174.6M $181.0M
YoY Change -14.21% -13.68% -13.22%
Cash & Equivalents $57.08M $67.87M $86.24M
Short-Term Investments $110.2M $106.7M $94.78M
Other Short-Term Assets $1.816M $569.1K $1.064M
YoY Change -16.79% 22.7% 112.89%
Inventory
Prepaid Expenses $1.816M $569.1K $1.064M
Receivables $6.210K $19.45K $19.25K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $169.1M $175.2M $182.1M
YoY Change -14.44% -13.68% -13.03%
LONG-TERM ASSETS
Property, Plant & Equipment $186.5K $217.0K $247.4K
YoY Change -39.51% -27.08% -17.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $259.5K $259.5K $259.5K
YoY Change 0.0% -3.39% -13.51%
Total Long-Term Assets $446.0K $476.4K $506.8K
YoY Change -21.45% -15.85% -18.09%
TOTAL ASSETS
Total Short-Term Assets $169.1M $175.2M $182.1M
Total Long-Term Assets $446.0K $476.4K $506.8K
Total Assets $169.5M $175.7M $182.6M
YoY Change -14.46% -13.69% -13.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $954.6K $556.0K $756.6K
YoY Change -33.05% -38.74% -55.25%
Accrued Expenses $807.5K $2.945M $2.485M
YoY Change -60.85% 72.97% 83.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $2.310M $4.034M $3.749M
YoY Change -41.21% 34.07% 17.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $76.42K $111.3K $145.3K
YoY Change -66.86% -86.39% -89.62%
Total Long-Term Liabilities $76.42K $111.3K $145.3K
YoY Change -66.86% -86.39% -89.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.310M $4.034M $3.749M
Total Long-Term Liabilities $76.42K $111.3K $145.3K
Total Liabilities $2.387M $4.145M $3.894M
YoY Change -42.63% 8.33% -15.22%
SHAREHOLDERS EQUITY
Retained Earnings -$152.9M -$146.6M -$137.7M
YoY Change 29.81% 34.19% 37.09%
Common Stock $278.1M $278.1M $278.0M
YoY Change 0.24% 0.26% 0.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $167.1M $171.5M $178.7M
YoY Change
Total Liabilities & Shareholders Equity $169.5M $175.7M $182.6M
YoY Change -14.46% -13.69% -13.04%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.324M -$8.827M -$10.85M
YoY Change -26.12% 0.85% -16.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$7.856M -$6.643M -$8.385M
YoY Change 6.4% 2.01% 10.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.969M -$11.75M -$26.63M
YoY Change 79476.51% -23.93%
Cash From Investing Activities -$2.969M -$11.75M -$26.63M
YoY Change 79476.51% -23.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -34.63K 4.920K 183.1K
YoY Change -359.98% -97.38% -99.87%
NET CHANGE
Cash From Operating Activities -7.856M -6.643M -8.385M
Cash From Investing Activities -2.969M -11.75M -26.63M
Cash From Financing Activities -34.63K 4.920K 183.1K
Net Change In Cash -10.86M -18.39M -34.83M
YoY Change 47.35% 190.11% -135.16%
FREE CASH FLOW
Cash From Operating Activities -$7.856M -$6.643M -$8.385M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1250703
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6231908
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
dei Entity File Number
EntityFileNumber
001-37410
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44059700
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41018024
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44026502
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36937014
dei Entity Central Index Key
EntityCentralIndexKey
0001633932
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#ShortTermInvestments
CY2021Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#ShortTermInvestments
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44073076
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43984346
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
dei City Area Code
CityAreaCode
778
dei Local Phone Number
LocalPhoneNumber
331-0962
dei Security12b Title
Security12bTitle
Common Shares
dei Trading Symbol
TradingSymbol
EPIX
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44073076
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67868096
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137825024
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
106727807
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
57102159
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
19450
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
489012
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
569092
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2181882
CY2022Q2 us-gaap Assets Current
AssetsCurrent
175184445
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6394534
CY2021Q3 us-gaap Assets Current
AssetsCurrent
197598077
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
216946
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
CY2022Q2 us-gaap Assets
Assets
175660846
CY2021Q3 us-gaap Assets
Assets
198165818
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3902899
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3808944
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130868
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
120719
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4033767
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3929663
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
111273
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
210251
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20352
CY2022Q2 us-gaap Liabilities
Liabilities
4145040
CY2021Q3 us-gaap Liabilities
Liabilities
4160266
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44073076
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43984346
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
278089136
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
277415176
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42109862
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36442620
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2128161
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146555031
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117775765
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
171515806
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175660846
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198165818
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20063752
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17985937
CY2022Q2 epix Financing Costs
FinancingCosts
3145
CY2021Q2 epix Financing Costs
FinancingCosts
16667
epix Financing Costs
FinancingCosts
10996
epix Financing Costs
FinancingCosts
18147
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2895542
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3117900
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9775082
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9942149
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9293221
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9366475
us-gaap Operating Expenses
OperatingExpenses
29849830
us-gaap Operating Expenses
OperatingExpenses
27946233
us-gaap Net Income Loss
NetIncomeLoss
-28779266
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
910
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-34084
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
30338
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-19239
CY2022Q2 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
417872
CY2021Q2 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
80394
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
974207
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
155293
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1929
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
568954
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-470132
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8872510
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8751211
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28824933
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28280311
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45767
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45667
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34349
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8826743
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8752011
us-gaap Net Income Loss
NetIncomeLoss
-28245962
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2951
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-51682
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8829694
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8752011
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28830948
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28245962
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44059700
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41018024
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44026502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36937014
us-gaap Net Income Loss
NetIncomeLoss
-28779266
us-gaap Net Income Loss
NetIncomeLoss
-28245962
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91340
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80665
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-170331
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Accretion Expense
AccretionExpense
10555
us-gaap Accretion Expense
AccretionExpense
5497
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-470132
epix Interest Income Operating Activities
InterestIncomeOperatingActivities
450580
epix Interest Income Operating Activities
InterestIncomeOperatingActivities
42719
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-571
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
0
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
69637
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
287374
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141977430
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16827
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-56920
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69956928
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
88873418
epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
6038227
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-26497
us-gaap Share Based Compensation
ShareBasedCompensation
5954444
us-gaap Share Based Compensation
ShareBasedCompensation
6652613
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-469562
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-104749
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1612790
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1145402
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
92390
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1770800
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20848215
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18032326
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
197959710
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57026103
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
148254180
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
22000000
epix Interest From Short Term Investments
InterestFromShortTermInvestments
326270
epix Interest From Short Term Investments
InterestFromShortTermInvestments
11337
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49379260
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35014766
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
149999985
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9229451
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
319832
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1186833
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
382
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
66926
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
89318
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
99384
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137825024
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56320763
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67868096
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145194181
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2020Q4 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
149
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153701
CY2020Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27369
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204985
CY2020Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6528704
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74101365
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
149999985
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
9168801
CY2022Q2 epix Cash Canada Deposit Insurance Corporation Insured Amount
CashCanadaDepositInsuranceCorporationInsuredAmount
100000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8752011
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
199697583
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104324
CY2021Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27360
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2500091
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9097919
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
187539408
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215508
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1863353
CY2021Q1 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
100
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
776985
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2663684
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12965247
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
205408071
CY2021Q2 epix Stock Issued During Period Issuance Cost
StockIssuedDuringPeriodIssuanceCost
60649
CY2021Q2 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
133
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256147
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61948
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2783944
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10903335
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
178714934
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
39566
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1591000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8829694
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
171515806
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106468599
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
51682
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of June 30, 2022, no products are in commercial production or use.</p>
epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.06
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as of the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Estimates and assumptions are reviewed quarterly.</p>
CY2022Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
310890
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106727807
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57026103
CY2021Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
76056
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57102159
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106700000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57100000
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
51682
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
317962
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1751052
CY2022Q2 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2021Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
240513
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
69295
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
190317
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
569092
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2181882
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
555962
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1425871
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2945398
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2062441
CY2022Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
401539
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
320632
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3902899
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3808944
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55162
epix Operating Lease Right Of Use Asset Addition
OperatingLeaseRightOfUseAssetAddition
323036
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80665
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
297533
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91340
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
216946
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
59094
epix Operating Lease Liabilities Addition
OperatingLeaseLiabilitiesAddition
323036
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
5497
us-gaap Operating Lease Payments
OperatingLeasePayments
69637
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
317990
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
330970
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
10555
us-gaap Operating Lease Payments
OperatingLeasePayments
99384
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
242141
CY2022Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.050
CY2020Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
127376
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
107024
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
20352
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
20352
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.87
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
323610
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.68
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
72390
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.46
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1297500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.64
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72910
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
175759
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.60
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7852061
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.15
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4275776
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.52
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7852061
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1297500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.04
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.73
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.84
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 epix Working Capital
WorkingCapital
171150678

Files In Submission

Name View Source Status
0001558370-22-012034-index-headers.html Edgar Link pending
0001558370-22-012034-index.html Edgar Link pending
0001558370-22-012034.txt Edgar Link pending
0001558370-22-012034-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220630.xsd Edgar Link pending
tmb-20220630x10q.htm Edgar Link pending
tmb-20220630x10q001.jpg Edgar Link pending
tmb-20220630x10q_htm.xml Edgar Link completed
tmb-20220630xex31d1.htm Edgar Link pending
tmb-20220630xex31d2.htm Edgar Link pending
tmb-20220630xex32d1.htm Edgar Link pending
tmb-20220630_cal.xml Edgar Link unprocessable
tmb-20220630_def.xml Edgar Link unprocessable
tmb-20220630_lab.xml Edgar Link unprocessable
tmb-20220630_pre.xml Edgar Link unprocessable